1

{Aprutumab: A Novel Option for FGFR2-Driven Growths

aprutumab-for-research-u696972
Aprutumab, {a specific ADC, represents {a significant advance in combating cancers fueled by FGFR2 alterations. This targeted therapy functions by directly binding to FGFR2, a tyrosine kinase often amplified in https://www.targetmol.com/compound/aprutumab
Report this page

Comments

    HTML is allowed

Who Upvoted this Story